Curcumin analog GO-Y030 inhibits tumor metastasis and glycolysis

Tumor metastasis is one of the worst prognostic features of cancer. Although metastasis is a major cause of cancer-related deaths, an effective treatment has not yet been established. Here, we explore the antitumor effects of GO-Y030, a curcumin analog, via various mechanisms using a mouse model. GO-Y030 treatment of B16-F10 melanoma cells inhibited TGF-& beta; expression and glycolysis. The invasion assay results showed almost complete invasion inhibition following GO-Y030 treatment. Mouse experiments demonstrated that GO-Y030 administration inhibited lung tumor metastasis without affecting vascular endothelial cells. Consistent with this result, GO-Y030 treatment led to the downregulation of MMP2 and VEGF & alpha;, inhibiting tumor invasion and metastasis. The silencing of eIF4B, a downstream molecule of S6, attenuated MMP2 expression. Our study demonstrates the novel efficacy of GO-Y030 in inhibiting tumor metastasis by regulating metastasis-associated gene expression via inhibiting dual access, glycolytic and TGF-& beta; pathways. Graphical Abstract

Automated summary

In this study, the antitumor effects of GO-Y030, a curcumin analog, were investigated in a mouse model. The results showed that GO-Y030 treatment inhibited the expression of TGF-β and glycolysis in melanoma cells, leading to the inhibition of tumor invasion and metastasis. Furthermore, GO-Y030 administration demonstrated efficacy in inhibiting lung tumor metastasis without affecting vascular endothelial cells.